No Data
No Data
BofA Securities Maintains Hutchmed (China)(HCM.US) With Buy Rating, Maintains Target Price $26
Hutchmed Announces NMPA Approval for Orpathys Supplemental New Drug Application
Hutchmed Gets China Approval for Non-Small Cell Lung Cancer Mutation
Express News | Reported Earlier, HUTCHMED Secures Full NMPA Approval For ORPATHYS In China To Treat Advanced MET Exon 14 NSCLC
Hutchmed's Lung Cancer Treatment Wins Chinese Approval
Express News | HUTCHMED (China) Ltd - Nmpa Full Approval for Orpathys (Savolitinib) in China